



SyntheticMR AB (publ) postpones the interim report for the third quarter of 2025

The Board of Directors of SyntheticMR AB (publ) has decided to postpone the publication of the interim report for the third quarter to November 28, 2025. The previously communicated publication date was November 26, 2025. The reason for the postponement is that the report is not yet finalized, as CEO Lena Åredal has been on an important business trip.

For more information please contact:

Lena Åredal, VD
Telefon: +46 (0)76-770 99 08

E-post: lena.aredal@syntheticmr.com

SyntheticMR AB (publ) develops and markets innovative imaging solutions that enhance neuroimaging workflow efficiency and diagnostic precision. SyntheticMR's SyMRI® solution measures brain absolute tissue properties and generates multiple contrast-weighted images, performs automatic segmentation of biomarkers, and delivers quantitative data in a single fast scan. Combinostics, a SyntheticMR company, offers the AI-powered cNeuro® suite of products that help clinicians make a difference in the lives of patients with neurological disorders. Our products are, among other things, CE-marked and FDA-approved, and we are listed on Spotlight Stock Market Exchange in Stockholm. SyntheticMR is headquartered in Linköping, Sweden, with an additional office in Tampere, Finland. For more information, please visit syntheticmr.com and combinostics.com.